These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 24724704)

  • 1. Letter to the editor.
    Muhonen T
    J Med Econ; 2014 Jun; 17(6):442. PubMed ID: 24724704
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter to the editor: author response.
    Rautenberg T
    J Med Econ; 2014 Jun; 17(6):443. PubMed ID: 24724705
    [No Abstract]   [Full Text] [Related]  

  • 3. Economic outcomes of sequences which include monoclonal antibodies against vascular endothelial growth factor and/or epidermal growth factor receptor for the treatment of unresectable metastatic colorectal cancer.
    Rautenberg T; Siebert U; Arnold D; Bennouna J; Kubicka S; Walzer S; Ngoh C
    J Med Econ; 2014 Feb; 17(2):99-110. PubMed ID: 24215550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetuximab.
    Graham J; Muhsin M; Kirkpatrick P
    Nat Rev Drug Discov; 2004 Jul; 3(7):549-50. PubMed ID: 15272498
    [No Abstract]   [Full Text] [Related]  

  • 5. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC).
    Lawrence D; Maschio M; Leahy KJ; Yunger S; Easaw JC; Weinstein MC
    J Med Econ; 2013 Dec; 16(12):1387-98. PubMed ID: 24102083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy in colorectal cancer.
    Rajpal S; Venook AP
    Clin Adv Hematol Oncol; 2006 Feb; 4(2):124-32. PubMed ID: 16728921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Some problems facing the molecular targeting therapy for colorectal cancer].
    Xu JM
    Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):321-3. PubMed ID: 19799077
    [No Abstract]   [Full Text] [Related]  

  • 8. Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer.
    Morse MA
    IDrugs; 2005 Dec; 8(12):974-7. PubMed ID: 16320126
    [No Abstract]   [Full Text] [Related]  

  • 9. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
    Venook AP
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Position statement of the Hungarian Radiotherapy and Oncology College on the insurance coverage of Vectibix (panitumumab)].
    Pikó B;
    Magy Onkol; 2009 Jun; 53(2):175-6. PubMed ID: 19581184
    [No Abstract]   [Full Text] [Related]  

  • 11. New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: the role of vascular endothelial growth factor.
    Vincenzi B; Santini D; Tonini G
    J Clin Oncol; 2006 Apr; 24(12):1957; author reply 1957-8. PubMed ID: 16622275
    [No Abstract]   [Full Text] [Related]  

  • 12. [New oncolytic agents and immunomodulators and their application].
    Lange R; Maring JG
    Ned Tijdschr Geneeskd; 2005 Oct; 149(40):2256-7; author reply 2257-8. PubMed ID: 16235808
    [No Abstract]   [Full Text] [Related]  

  • 13. Molecular mechanisms and targeting of colorectal cancer.
    Vanhoefer U
    Semin Oncol; 2005 Dec; 32(6 Suppl 8):7-10. PubMed ID: 16360005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The changing paradigm of colorectal cancer therapy: the impact of vascular endothelial growth factor and epidermal growth factor and epidermal growth factor receptor inhibition. Introduction.
    Chase JL
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):17S. PubMed ID: 18980547
    [No Abstract]   [Full Text] [Related]  

  • 15. [Impact of mutational status of KRAS in the care of patients with colorectal cancer metastasis].
    Assenat E; Ychou M
    Bull Cancer; 2009 Dec; 96 Suppl():S41-6. PubMed ID: 20034869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
    Chase JL
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Panitumumab, a monoclonal anti epidermal growth factor receptor antibody in colorectal cancer: another one or the one?
    Messersmith WA; Hidalgo M
    Clin Cancer Res; 2007 Aug; 13(16):4664-6. PubMed ID: 17699842
    [No Abstract]   [Full Text] [Related]  

  • 18. [Monoclonal antibodies therapies for colorectal cancer: cétuximab, panitumumab and bevacizumab].
    Piront P; Van Daele D; Belaiche J; Polus M
    Rev Med Liege; 2009; 64(5-6):274-8. PubMed ID: 19642458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of new agents in the treatment of colorectal cancer.
    Ruiz de Erenchun F
    Oncology; 2005; 68(2-3):162; author reply 162. PubMed ID: 16097096
    [No Abstract]   [Full Text] [Related]  

  • 20. Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer.
    Jackson C; Cunningham D
    Eur J Cancer; 2008 Mar; 44(5):652-62. PubMed ID: 18313913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.